RxDoctor Payments Data

Michael Callaghan, MD

Radiation Oncology · Pocatello, IDNPI 1316978539

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 79 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 13.4% — the pattern of someone who eats at a lot of different presentations.

$1,586in general payments, 2019–2025

Across 79 payments — averaging $20.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$213
  • AstraZeneca$147
  • Jazz Pharmaceuticals Inc.$136
  • Merck$83
  • Lilly USA, LLC$80
  • AbbVie$75
  • plus $852 from 26 others

What the payments were for

  • Food & beverage$1,586100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,586 in reported general payments places this provider in the 70th percentile of 22 radiation oncology providers in Idaho.

See all radiation oncology providers in Idaho

Medicare billing

Part B allowed, 2024
$179,553
Medicare patients
169
Services billed
2,053

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Tamsulosin Hcl118$1,827
Venlafaxine Hcl ErVenlafaxine Hcl14$211
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen13$179

Paid to pharmacies, not to this prescriber.

Other radiation oncology in Pocatello

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →